<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00677339</url>
  </required_header>
  <id_info>
    <org_study_id>AVDAPT 1</org_study_id>
    <nct_id>NCT00677339</nct_id>
  </id_info>
  <brief_title>L-arginine and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis (TB)</brief_title>
  <acronym>AVDAPT</acronym>
  <official_title>Phase 3 Trial of Oral L-arginine and / or Vitamin D as Adjunctive Therapies in Pulmonary Tuberculosis in Papua Province, Indonesia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menzies School of Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Health Research and Development (NIHRD), Indonesia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Australian National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Menzies School of Health Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether adjunctive L-arginine and vitamin D can
      improve response to standard short course TB therapy in people with newly diagnosed pulmonary
      TB.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The two major pathways proposed to mediate macrophage mycobacterial killing in humans are the
      arginine-nitric oxide and Vitamin D-1,25 dihydroxyvitamin D pathways. Our aim is to determine
      if the key immunomodulatory agents L-arginine and vitamin D can improve the rapidity and
      magnitude of the microbiological and clinical response in pulmonary TB. We will test the
      following hypotheses in newly-diagnosed TB patients in Timika, Papua, Indonesia:

      Our specific aims are to:

        1. Determine whether supplementation with L-arginine and/or vitamin D is safe, and results
           in more rapid improvement in clinical, mycobacterial, immunological, radiological,
           physiological and functional measures of treatment outcome. We will randomise patients
           with pulmonary TB to receive, in addition to standard TB therapy, adjunctive arginine,
           vitamin D and / or placebo in a randomised, double-blind factorial 2x2 design. We will
           relate serial measurements of plasma concentrations of L-arginine and vitamin D, and
           immunological responses (pulmonary NO production, T cell function and phenotype) to
           measures of treatment outcome [mycobacterial (sputum smear clearance and culture
           conversion), physiological (spirometry), clinical (symptoms and weight), radiological
           (chest Xray) and functional (six-minute walk test, modified St George Respiratory
           Questionnaire)].

        2. Determine whether pulmonary production of NO is inversely related to disease severity at
           presentation. Baseline and serial measures of NO production will be related to disease
           severity and the magnitude and rapidity of clinical response
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of pulmonary TB patients who are culture negative at 1 month</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in improvement in composite clinical endpoint comprising weight, cough clearance and FEV1 at 2 months.</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in plasma L-arginine concentration</measure>
    <time_frame>week 0, 2, 4, 8, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma 25(OH)D3 concentration</measure>
    <time_frame>week 0, 2, 4, 8, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death, clinical failure and default independently, and 'death or clinical failure or default'.</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypercalcaemia</measure>
    <time_frame>week 0, 2, 4, 8, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal side effects</measure>
    <time_frame>weekly to week 8 then at week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum smear conversion time</measure>
    <time_frame>weekly to week 8 then at week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological improvement (percentage lung involvement on CXR at 2 months).</measure>
    <time_frame>week 0, 2, 4, 8, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cough clearance</measure>
    <time_frame>weekly to week 8 then at week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in improvement in percent predicted FEV1 at 2 and 6 months.</measure>
    <time_frame>weeks 0, 4, 8, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight gain</measure>
    <time_frame>weekly to week 8 then at week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological improvement (exhaled NO)</measure>
    <time_frame>week 0, 2, 4, 8, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological improvement (T cell CD3Î¶ expression and T cell function)</measure>
    <time_frame>week 0, 2, 4, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional improvement measured using six minute walk test</measure>
    <time_frame>week 0, 4, 8, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment using modified St George Respiratory Questionnaire.</measure>
    <time_frame>weeks 0, 4, 8, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary end points stratified by HIV status.</measure>
    <time_frame>weekly to week 8 then at week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary end points stratified by baseline vitamin D and L-arginine status.</measure>
    <time_frame>weekly to week 8 then week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary end points stratified by ethnicity (Papuan and non-Papuan patients).</measure>
    <time_frame>weekly to week 8 then week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Smear Positive Pulmonary Tuberculosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active L-arginine plus active vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo L-arginine plus active Vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active L-arginine plus placebo vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo L-arginine plus placebo vitamin D</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-arginine</intervention_name>
    <description>L-arginine 6g orally daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Argimax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Cholecalciferol 50000 IU once monthly orally</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Calciferol Strong</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo L-arginine</intervention_name>
    <description>placebo L-arginine once daily</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Vitamin D</intervention_name>
    <description>placebo vitamin D orally once monthly</description>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults &gt;15 years with sputum smear positive pulmonary TB

          -  New cases only

          -  Agree to continue treatment in Timika for the full six month course of treatment -Not
             pregnant

          -  Consent to enroll in the study.

        Exclusion Criteria:

          -  hypercalcaemia (ionized calcium &gt;1.32 mmol/L) identified at baseline

          -  taking arginine or vitamin D
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas M Anstey, MBBS</last_name>
    <role>Study Director</role>
    <affiliation>Menzies School of Helath Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna P Ralph, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Australian National University, Canberra, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franciscus Thio, MPPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>District Ministry of Health, Timika</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Morris, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Menzies School of Health Research, Northern Territory, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enny Kenangalem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Papuan Community Health and Development Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeanne R Poespoprodjo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mimika District Health Authority</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard N Price, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Menzies School of Health Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tonia Woodberry, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Menzies School of Health Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul M Kelly, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Australian Capital Territory Department of Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emiliana Tjitra, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Health Research and Development (NIHRD), Indonesia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandjaja Sandjaja, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Health Research and Development (NIHRD), Indonesia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dina B Lolong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Health Research and Development</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Chatfield, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Health and Medical Research Council (Australia) Clinical Trials Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ivan Bastian, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Medical and Veterinary Pathology, South Australia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Timika Tuberculosis Clinic and Community Hospital</name>
      <address>
        <city>Timika</city>
        <state>Papua Province</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2008</study_first_submitted>
  <study_first_submitted_qc>May 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2008</study_first_posted>
  <last_update_submitted>January 17, 2012</last_update_submitted>
  <last_update_submitted_qc>January 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Menzies School of Health Research</investigator_affiliation>
    <investigator_full_name>Dr Anna Ralph</investigator_full_name>
    <investigator_title>Global and Tropical Health</investigator_title>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>Adjunctive therapy</keyword>
  <keyword>L-arginine</keyword>
  <keyword>Nitric oxide</keyword>
  <keyword>Vitamin D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

